Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.

Objective: To review the therapeutic profile of elranatamab, a novel bispecific T-cell-redirecting therapy, in treating relapsed or refractory (R/R) multiple myeloma (MM).

Data Sources: A PubMed search was conducted for English-language articles published from January 2000 through June 2024, using the search terms: , and "" Additional data were obtained from ClinicalTrials.gov and other pertinent publications and meeting abstracts.